Tough Going Forces Chinese Biotechs To Form Domestic Alliances
Deals among domestic Chinese biotechs are growing fast, reflecting a need to huddle up amid tightening scrutiny over biotech deal-making and an unusually competitive immuno-oncology market.
You may also be interested in...
BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.
Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.